Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR3”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Testing effectiveness (Phase 2)Study completedNCT04265651
What this trial is testing

Study of Infigratinib in Children With Achondroplasia

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 84
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Early research (Phase 1)Ended earlyNCT05242822
What this trial is testing

Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Who this might be right for
Solid Tumor, AdultIntrahepatic CholangiocarcinomaUrothelial Carcinoma
Kinnate Biopharma 54
Testing effectiveness (Phase 2)Study completedNCT00866138
What this trial is testing

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Who this might be right for
Multiple Myeloma
AB Science 24
Not applicableStudy completedNCT05151341
What this trial is testing

Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors

Who this might be right for
Bladder Cancer
Institut de Cancérologie de Lorraine 190
Testing effectiveness (Phase 2)Looking for participantsNCT04945148
What this trial is testing

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide

Who this might be right for
Glioblastoma, IDH-wildtype
Hopital Foch 640
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Large-scale testing (Phase 3)Looking for participantsNCT07218380
What this trial is testing

Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT04917809
What this trial is testing

Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Who this might be right for
Bladder CancerRecurrent Bladder CancerFGFR3 Gene Mutation
Memorial Sloan Kettering Cancer Center 20
Large-scale testing (Phase 3)Enrolling By InvitationNCT06873035
What this trial is testing

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 24
Testing effectiveness (Phase 2)Ended earlyNCT03123055
What this trial is testing

B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Who this might be right for
Locally Advanced or Metastatic Urothelial Cell CarcinomaUrinary Bladder DiseaseUrological Diseases
Rainier Therapeutics 28
Not applicableNot Yet RecruitingNCT07388966
What this trial is testing

Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia

Who this might be right for
AchondroplasiaHypochondroplasia
SYSNAV 40
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Not applicableActive Not RecruitingNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Not applicableStudy completedNCT00106977
What this trial is testing

Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)

Who this might be right for
CraniosynostosisMuenke Syndrome
National Human Genome Research Institute (NHGRI) 137
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05145010
What this trial is testing

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 300
Early research (Phase 1)Looking for participantsNCT06915753
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Who this might be right for
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+11 more
Tyra Biosciences, Inc 100
Load More Results